Adenovirus vector-based vaccines for human immunodeficiency virus type 1

Dan H. Barouch, Gary J. Nabel

Research output: Contribution to journalArticlepeer-review

Abstract

Recombinant adenovirus (rAd) vectors have received considerable attention for gene therapy because of their high transduction efficiency. However, recombinant gene expression from rAd vectors elicits rapid and potent immune responses to foreign transgene products. Such immunogenicity limits the duration of transgene expression and poses a major challenge to the use of rAd vectors for gene therapy. In contrast, the inherent immunogenicity of these vectors is a desirable feature for vaccine development. The immunogenicity and protective efficacy of rAd vector-based vaccines have now been demonstrated in a number of animal models, and rAd vaccines for a variety of pathogens are currently being explored in early-phase clinical trials. In this review, we describe progress in the development of rAd vector-based vaccines with a focus on human immunodeficiency virus type 1.

Original languageEnglish (US)
Pages (from-to)149-156
Number of pages8
JournalHuman Gene Therapy
Volume16
Issue number2
DOIs
StatePublished - Feb 2005
Externally publishedYes

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'Adenovirus vector-based vaccines for human immunodeficiency virus type 1'. Together they form a unique fingerprint.

Cite this